ENGN

MKT CAP:$410M

enGene Holdings Inc.

Market Cap

$410M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$8.34-$0.51 (-5.82%)

Apr 20, 2026

Company Details

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candida...

CEO

Ronald H. W. Cooper

IPO Date

Feb 1, 2022

Website

www.engene.com

Key Metrics TTM

Revenue

$480.0K

— YoY

Net Income

-$107M

EPS (Diluted)

-$2.13

Free Cash Flow

-$98M

Revenue / Share

$0.01

Gross Margin

-34.0%

Operating Margin

-11167.1%

Net Margin

-22247.1%

FCF Margin

-20320.4%

P/S

853.8x

P/E

—

Earnings Reports

Q4 2025

Dec 22, 2025

$0-100.0%EPS -$0.74

Q3 2025

Sep 11, 2025

$0EPS -$0.57

Q1 2025

Mar 10, 2025

$0EPS -$0.48

FY 2024

Dec 19, 2024

$0EPS -$1.46

Q4 2024

Dec 19, 2024

$480.0KEPS -$0.34

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	$0
Q3 22	$0	$0	-$5M
Q4 22	$0	$0	-$7M
Q1 23	$0	$0	-$5M
Q2 23	$0	$0	-$5M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$10M
Q1 24	$0	-$80.0K	-$11M
Q2 24	$0	-$78.0K	-$17M
Q3 24	$0	-$82.0K	-$17M
Q4 24	$480.0K	$240.0K	-$17M
Q1 25	$0	-$102.0K	-$27M
Q3 25	$0	-$130.0K	$30M
Q4 25	$0	-$171.0K	-$39M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	9388.3x	—
Q1 25	7104.9x	—
Q3 25	386.9x	—
Q4 25	736.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$796.2K	-$796.2K
Q3 22	-$5M	-$5M
Q4 22	-$5M	-$5M
Q1 23	-$6M	-$6M
Q2 23	-$4M	-$4M
Q3 23	-$7M	-$7M
Q4 23	-$7M	-$7M
Q1 24	-$7M	-$8M
Q2 24	-$14M	-$14M
Q3 24	-$7M	-$7M
Q4 24	-$20M	-$20M
Q1 25	-$26M	-$26M
Q3 25	-$26M	-$26M
Q4 25	-$25M	-$25M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q3 22	$4.0K
Q4 22	$34.0K
Q1 23	$13.0K
Q2 23	$10.0K
Q3 23	$157.0K
Q4 23	$138.0K
Q1 24	$506.0K
Q2 24	$179.0K
Q3 24	$2.0K
Q4 24	$238.0K
Q1 25	$299.0K
Q3 25	$704.0K
Q4 25	$437.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 23	—	—
Q3 23	—	+17.8%
Q4 23	—	+59.7%
Q1 24	—	+132.5%
Q2 24	—	+265.4%
Q3 24	—	+168.2%
Q4 24	—	+71.8%
Q1 25	—	+147.0%
Q3 25	—	-273.0%
Q4 25	—	+135.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q3 22	$30.0K	—
Q4 22	$32.0K	—
Q1 23	$20.0K	—
Q2 23	$39.0K	—
Q3 23	$37.0K	—
Q4 23	$3M	—
Q1 24	$291.0K	—
Q2 24	$2M	—
Q3 24	$1M	—
Q4 24	$2M	345.0%
Q1 25	$2M	—
Q3 25	$3M	—
Q4 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A
Q3 22	$4M	$644.0K
Q4 22	$5M	$1M
Q1 23	$4M	$947.0K
Q2 23	$3M	$1M
Q3 23	$4M	$2M
Q4 23	$6M	$4M
Q1 24	$6M	$4M
Q2 24	$10M	$6M
Q3 24	$12M	$7M
Q4 24	$11M	$8M
Q1 25	$20M	$6M
Q3 25	$23M	$7M
Q4 25	$32M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$909.6K	$0	$909.6K
Q3 22	$774.9K	$0	$774.9K
Q4 22	$457.0K	$0	$457.0K
Q1 23	$314.2K	$0	$314.2K
Q2 23	$474.4K	$0	$474.4K
Q3 23	$269.1K	$0	$269.1K
Q4 23	$82M	$0	$82M
Q1 24	$86M	$79.0K	$86M
Q2 24	$265M	$75.0K	$265M
Q3 24	$258M	$75.0K	$258M
Q4 24	$173M	$65M	$238M
Q1 25	$62M	$152M	$214M
Q2 25	$58M	$160M	$217M
Q3 25	$33M	$169M	$202M
Q4 25	$50M	$144M	$194M
Q1 26	$37M	$239M	$276M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	16M	—	—
Q3 22	16M	0.0%	—
Q4 22	16M	0.0%	—
Q1 23	16M	0.0%	—
Q2 23	16M	0.0%	0.0%
Q3 23	16M	0.0%	0.0%
Q4 23	31M	+98.0%	+98.0%
Q1 24	23M	-25.9%	+46.7%
Q2 24	39M	+70.0%	+149.4%
Q3 24	44M	+12.0%	+179.3%
Q4 24	45M	+2.1%	+44.1%
Q1 25	51M	+13.0%	+119.7%
Q3 25	51M	+0.2%	+29.5%
Q4 25	51M	+0.4%	+16.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	33
Q1 24	$0	33
Q2 24	$0	33
Q3 24	$0	33
Q4 24	$8.4K	57
Q1 25	$0	57
Q3 25	$0	57
Q4 25	$0	730K

Revenue / Employee